Healthcare Industry News: chronic kidney disease
News Release - May 2, 2006
Sorin Group Presents New Heart Valve Prostheses Designed to Restore the Patients' Natural Physiological ConditionsSorin Group has Organized at the AATS Congress in Philadelphia a Satellite Symposium to Present the Freedom SOLO Aortic Valve and the New MEMO 3D Annuloplasty Ring (CE and FDA Approval Pending)
PHILADELPHIA, Pennsylvania, May 2 (HSMN NewsFeed) -- Sorin Group, Europe's largest medical technology company specialized in the treatment of cardiovascular diseases and leader in Cardiac Surgery, presented today, at the 86th AATS Congress, the latest clinical results on Freedom SOLO valve (available in Europe) and MEMO 3D Annuloplasty Ring (CE and FDA pending) during the Satellite Symposium "Aortic and Mitral Valves Treatment: back to physiological conditions" chaired by Dr. Hargrove (Presbyterian Medical Center, Philadelphia) and Dr. Beholz (Charité University Hospital, Berlin, Germany).
Dr. Hargrove presented his experience in mitral valve repair using AnnuloFlex Ring (Sorin Group flexible annuloplasty ring) with a minimally invasive surgical approach.
Dr. Repossini (Istituto Humanitas-Gavazzeni, Bergamo, Italy) presented his clinical results and long-term experience with Freedom SOLO aortic valve.
Freedom Solo is a unique pericardial valve, easy to implant in supra-annular positioning, designed to mimic the native aortic valve and ensuring excellent haemo-dynamic performance.
Prof. Fischlein (Friederich-Alexander University Hospital, Erlangen, Germany) introduced the innovative Memo 3D ring design and presented the first clinical implant.
MEMO 3D represents an innovative and unique achievement in the growing segment of heart valve repair, confirming Sorin Group's strong commitment to product innovation and new therapies. "Memo 3D is the result of the combination of two major Sorin Group in house technologies which lead to a device able to restore the natural mitral annulus three-dimensional motility during cardiac cycle thanks to an innovative stent-like core structure. We can say this ring represents a real break-through in cardiac surgery practice," said Franco Vallana, President of the Cardiac Surgery Business Unit. Memo 3D, currently undergoing FDA Pre-Market Review, will soon be launched both in the European and US markets.
At the AATS meeting, where Sorin Group celebrates 20 years of clinical experience with its Carbomedics mechanical heart valves, Sorin Group is also present with a number of further events: Dr. Bavaria (Hospital of the University of Pennsylvania, Philadelphia) presenting technical considerations on Sorin Group Carbo-Seal Valsalva AAP, the first aortovalvular prosthesis with Valsalva sinuses; Dr. McCarty (Pinnacle Health at Harrisburg Hospital, Harrisburg, Pennsylvania) presenting the Novadaq system (distributed in the US by CarboMedics); Dr. Repossini and Dr. Beholz performing wet-labs on pig hearts in order to demonstrate the easy suturing technique of Freedom SOLO.
About MEMO 3D Annuloplasty Ring
- Innovative cell-structure design, capable of mimicking the physiological three-dimensional motility of the native mitral annulus and accommodating the anatomical saddle shape;
- Shape memory and super-elastic alloy core, aimed at restoring the native shape and function;
- Sorin Group's exclusive CarbofilmTM coating for enhanced haemo- and bio-compatibility;
- Ease of implant, according to a pre-defined line and thanks to a particular configuration of the silicon filler.
Sorin Group (Reuters code: SORN.MI), a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. Sorin Group includes: Dideco, CarboMedics, COBE Cardiovascular, Stöckert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Soludia. Sorin Group has more than 4,700 employees working at facilities in more than 80 countries throughout the world to serve over 5,000 public and private treatment centers.
Source: Sorin Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.